ILMN|Analyst Targets
ILMN|Company Info
ILMN|Insider Trading
ILMN|Fundamentals
ILMN|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $1.56 | - | - |
| Q3'26 | $1.38 | $1.44 | +4.1% |
| Q2'26 | $1.23 | $1.31 | +6.8% |
| Q1'26 | $1.05 | $1.15 | +9.0% |
| Q1'25 | $0.94 | $0.97 | +3.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $1.3B | - | - |
| Q3'26 | $1.2B | $1.1B | -4.1% |
| Q2'26 | $1.2B | $1.2B | +0.6% |
| Q1'26 | $1.1B | $1.1B | +1.7% |
| Q1'25 | - | $1.0B | - |
ILMN|Monthly Returns
Market Data
ILMN Stock Snapshot
- Market cap
- 29.15B
- P/E ratio
- 32.6
- Day range
- $191.25 – $200.00
- News sentiment
- 53/100 · Neutral
- Analyst target
- $261.45 (+35.5%)
- Consensus
- Hold · 28 analysts
Momentum is working in ILMN's favour - it ranks in the upper part of DailyIQ's momentum universe. In Healthcare, names this size usually take direction from sector flows before company-level news.
Behaviour On Record
What ILMN's own history says about today's numbers
- Realized volatility (21d)
- 73.3% 95th pct
- Below its peak
- -62.2%
- vs 200-day average
- +6.8%
- Up days (1y)
- 52%
Illumina, Inc. is currently running 73.3% annualised volatility over the last 21 sessions. Measured against ILMN's own 13 years of daily returns rather than a market-wide average, that is the 95th percentile — an extreme by its own standards, against a typical reading of 36.9%.
ILMN is trading -62.2% below its running peak. Across 13 full years on file, its median worst-drawdown-in-a-year was -34.4%, and the deepest was -60.1% in 2023. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.
Price sits +6.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 56th percentile — a somewhat wider gap than its own norm. Over the past year ILMN closed higher on 52% of sessions, and it is currently 2 sessions into a falling streak.
On November specifically: over 13 years of records, ILMN finished the month higher 6 of 13 times, with a median return of -0.6% and an average of +2.1%. Its strongest month historically has been January at +4.5% on average, its weakest February at -3.4%.
Overnight risk is measurable too: ILMN has opened more than 2% away from the prior close in 171 of 3,267 sessions (5.2% of the time), with the largest gaps running +8.1% and -10.2%.
Across the last 3 dated reports on file, ILMN moved an average of 3.2% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.5% and a largest of -8.3%.
All figures computed from 3,268 daily closes between 2013-11-22 and 2026-11-20, split-adjusted, recomputed daily. Percentiles are against ILMN's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of ILMN's sector?
Illumina, Inc. sits in the Health Care sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #5 of 12
- Sector state
- Leading
- Sector rotation score
- 82
Analyst Rating Changes
Are analysts turning bullish or bearish on ILMN?
Citigroup most recently reiterated its rating on Illumina, Inc. to Sell on Nov 2, 2026 with a price target of $210 (from $113). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.
- Latest action
- Citigroup: Sell
- 90-day upgrades
- 1
- 90-day downgrades
- 0
- Net rating momentum
- +1
Earnings Release, Scored
What did Illumina, Inc.'s latest earnings release say?
Most important lines
- 1
(b) Excludes the impacts of International Emergency Economic Powers Act (IEEPA) tariff refunds expected to be recovered, consisting primarily of a $79 million benefit recognized as a reduction to cost of revenue in Q3 2026 and a reduction to revenue of $37 million for the portion of tariff refunds that we expect to credit to customers.
New this quarter - 2
Organic revenue growth greater than 4% and ROW organic revenue growth greater than 5%, both unchanged versus prior guidance.
New this quarter - 3
Revenue excluding tariff refunds was $1.17 billion, up 4.7% after also excluding the impacts of currency, acquisitions, and the Greater China region (“ROW 1 organic revenue growth”).
New this quarter
Peers & ETF holders
ILMN peers & ETF holders
Diagnostics & ResearchMarket cap · today
News & sentiment
What is the news saying about ILMN?
ILMN fell 28.0% over the month to Nov 20. News tone held between 0 and 73 from Oct 20 to Nov 5, then jumped to 65 on Nov 9.
Technical analysis
How strong is ILMN's momentum right now?
On the daily chart ILMN ranks at the 98th percentile for momentum against 1,063 stocks and ETFs, a bullish reading.
Institutional ownership
Are big funds buying or selling ILMN?
110 of the 207 tracked managers added to ILMN in their latest 13F and 94 trimmed. Together they own 93.2% of the company, worth $38.5B. Fidelity and BlackRock alone hold 21.2%.
- 1FMR LLC (Fidelity)10.72%$4.4B positionAdded 257.8% last quarter
- 2BlackRock, Inc.10.49%$4.3B positionTrimmed 17.4% last quarter
- $2.7B positionAdded 50.1% last quarter
- 4Capital World Investors6.54%$2.7B positionTrimmed 35.9% last quarter
- 5State Street Corp4.76%$2.0B positionAdded 10.5% last quarter
- $1.7B positionTrimmed 4.3% last quarter
- $1.6B positionTrimmed 7.6% last quarter
- 8JPMorgan Chase & Co3.27%$1.3B positionAdded 318.4% last quarter
- $1.2B positionAdded 43.2% last quarter
- 10PRIMECAP Management Co2.31%$955.4M positionTrimmed 0.7% last quarter
Congressional trading
Is Congress trading ILMN?
4 members of Congress disclosed 8 ILMN trades between Dec 28, 2018 and Oct 27, 2026: 4 buys and 4 sells, about $64.0K in estimated value.
What stands out
Click one to highlight its trades in the chartDiscover more
How has ILMN done against its peers?
Over the six months to Nov 20, ILMN returned +35.6%. Of the 15 related stocks and ETFs, 8 did better, led by CRL at +101.4%.
- 1CRLCharles River Laboratories International, Inc.up 101.4%+65.9 pts
- 2MTDMettler-Toledo International Inc.up 54.0%+18.4 pts
- 3RVTYRevvity, Inc.up 53.2%+17.6 pts
- 4AAgilent Technologies, Inc.up 50.3%+14.7 pts
- 5TMOThermo Fisher Scientific Inc.up 48.2%+12.6 pts
- 6MEDPMedpace Holdings, Inc.up 44.7%+9.1 pts
- 7IQVIQVIA Holdings Inc.up 43.3%+7.7 pts
- 8LHLabcorp Holdings Inc.up 42.6%+7.0 pts
- 9ILMNThis stockup 35.6%
- 16XLVHealth Care Select Sector SPDR Fundup 20.5%−15.1 pts